文献速递血栓与止血

罗米司亭在妊娠期免疫性血小板减少症患者中的使用

Romiplostim use in pregnant women with immune thrombocytopenia.
PubMed 文献 · Am J Hematol · 2022-10-10

妊娠期免疫性血小板减少症(ITP)治疗缺乏母体用药胎儿安全性证据。妊娠监测项目(PSP)收集2017-2020年186例妊娠前20天至妊娠结束暴露于罗米司亭的女性妊娠、出生结局和不良事件信息,未发现针对母亲、胎儿或婴儿的特定安全性信号。

要点

  • 186例妊娠期暴露于罗米司亭的女性中,71例(38%)为孕前暴露,74例(40%)为孕早期暴露。
  • 已知妊娠结局的86例母亲中,46例(53%)发生至少1次妊娠相关严重不良事件,约2/3由基础ITP所致。
  • 已知出生结局的92例母亲中,60例(65%)妊娠正常,16例(17%)出现并发症,12例(14%)自然流产/死产。

核心结论

  • 对暴露于罗米司亭的女性妊娠进行回顾未发现针对母亲、胎儿或婴儿的任何特定安全性担忧。

研究设计与样本

  • 妊娠监测项目(PSP)收集2017-2020年186例从妊娠前20天至妊娠结束暴露于罗米司亭女性的妊娠、出生结局和不良事件信息。
  • 128例女性有暴露时间信息;71例(38%)为孕前暴露。

主要发现

  • 孕早期、孕中期、孕晚期暴露分别为74例(40%)、22例(12%)、44例(24%),15例在超过1个孕期暴露。
  • 已知妊娠结局的86例母亲中,46例(53%)发生至少1次妊娠相关严重不良事件,约2/3由基础ITP所致。
  • 已知出生结局的92例母亲中,60例(65%)妊娠正常,16例(17%)出现并发症,12例(14%)自然流产/死产,3例(3%)异位妊娠,1例(1%)葡萄胎。
  • 12例新生儿血小板减少症婴儿中7例出院前血小板减少症缓解,全部12例均出院。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment for immune thrombocytopenia (ITP) in pregnancy is hampered by the lack of fetal safety evidence of maternally-administered medications. The Pregnancy Surveillance Program (PSP) collected patient information from 2017-2020 for pregnancy, birth outcomes, and adverse events (AEs) for 186 women exposed to romiplostim from 20 days before pregnancy to the end of pregnancy. Timing of exposure was available in 128 women. Seventy-one mothers (38%) had prepregnancy exposure to romiplostim; intrapartum exposure was known for the first (for many mothers when they discovered their pregnancy), second, and third trimesters for 74 (40%), 22 (12%), and 44 (24%) mothers, respectively, with 15 mothers exposed during >1 trimester. Among the 86 mothers with known pregnancy outcomes, 46 (53%) had at least one pregnancy-related serious AE (SAE); approximately 2/3 of SAEs were due to underlying ITP. Of 92 mothers with known birth outcomes, 60 (65%) had a normal pregnancy and 16 (17%) had complications, with both categories including term and preterm births; there were 12 (14%) spontaneous miscarriages/stillbirths, 3 (3%) ectopic pregnancies, and 1 (1%) molar pregnancy. Most abnormal births resulted from abnormal pregnancies. There were five neonatal/postnatal AEs of note: inguinal hernia, cytomegalovirus infection, trisomy 8 (third trimester single-dose romiplostim exposure), single umbilical artery without known anomalies, and development of autism at age 2 years. Seven of 12 infants with neonatal thrombocytopenia had resolution of thrombocytopenia before discharge; all 12 were discharged. Review of pregnancies in women exposed to romiplostim did not reveal any specific safety concerns for mothers, fetuses, or infants.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Bussel JB, Cooper N, Lawrence T, et al. Romiplostim use in pregnant women with immune thrombocytopenia. Am J Hematol. 2022. PMID: 36156812. doi:10.1002/ajh.26743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。